Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 4,335 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 4,335 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $165.87, for a total value of $719,046.45. Following the completion of the sale, the chief financial officer now directly owns 103,697 shares of the company’s stock, valued at $17,200,221.39. This represents a 4.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Stock Down 1.3 %

Shares of NASDAQ NTRA opened at $174.24 on Wednesday. The business has a fifty day moving average of $167.26 and a two-hundred day moving average of $139.52. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52-week low of $66.68 and a 52-week high of $183.00. The stock has a market cap of $23.00 billion, a PE ratio of -99.00 and a beta of 1.66.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.95) earnings per share. As a group, equities research analysts expect that Natera, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently bought and sold shares of the business. Blue Trust Inc. boosted its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Quarry LP raised its holdings in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after buying an additional 190 shares during the last quarter. Versant Capital Management Inc lifted its position in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. Covestor Ltd grew its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the last quarter. Finally, Principal Securities Inc. increased its position in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on NTRA. TD Cowen increased their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Guggenheim increased their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Morgan Stanley boosted their target price on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. The Goldman Sachs Group increased their price target on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, Barclays began coverage on shares of Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $165.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.